Cellectis

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update. Full press release available here: https://lnkd.in/excyt9ng

Autologous CAR T-cell therapy is limited for cancer treatments.   Why?   🔹 Accessibility challenges The product must be generated from the patient’s T cells, requiring custom production. Many cancer patients have their T cells severely affected by both prior treatments and by cancer itself. This can limit the effectiveness of CAR T-cell therapies generated from patients’ cells.   🔹 High costs & manufacturing bottlenecks Each patient's cells constitute a separate batch, requiring dedicated equipment and processing suites. This leads to very high costs and reduced gross margins.   The future is allogeneic.   Allogeneic combines the scalability and accessibility of traditional pharmaceuticals with the advanced efficacy of personalized medicine. Here’s why:   🔶 Off-the-shelf accessibility Allogeneic therapies use cells from healthy donors, which are genetically engineered and stored in large batches, ready for immediate use. 🔶 Consistency and quality Healthy donor cells ensure higher quality and uniformity compared to autologous therapies.   🔶 Scalable & Broader patient access A single donor’s cells can treat multiple patients.   Allogeneic therapy offers hope for faster and widely accessible solutions for hard-to-treat diseases like cancers.   Doubts? Read the interview of our CBO & CFO Arthur Stril in Technology Networks: https://lnkd.in/e-q_6Yjp

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025. To read the press release: https://lnkd.in/e8F2TvNJ

Internalizing manufacturing in cell and gene therapy: a strategic move?   As the cell and gene therapy industry matures, companies face a critical decision: should they internalize manufacturing or rely on contract manufacturing organizations (CMOs)?   While this shift comes with significant benefits, it also presents challenges that require careful planning. Here’s a closer look:   Key Benefits: ✅ Greater control over quality & consistency – ensures tighter oversight of production ✅ Faster turnarounds times – avoids CMO bottlenecks and accelerates clinical timelines ✅ Process optimization – eliminates reliance on expensive external partners and enable process optimization ✅  Better regulatory alignment – directly managing compliance with evolving global standards   Considerations & Challenges: ❗High upfront investment – requires significant capital for facility setup, equipment, and talent ❗ Operational complexity – running a GMP-compliant facility demands expertise in manufacturing, supply chain, and regulatory affairs ❗ Scalability factors – be prepared to adapt capacity to fluctuating demand ❗ Strategic focus – balancing internal manufacturing with R&D and commercialization efforts requires strong leadership   Anything else you’d add? Drop it in the comments.

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at the AACR-IO 2025 meeting. Full press release available here: https://lnkd.in/eff9ccVY #AmericanAssociationForCancerResearch, #AACR-IO

Can CAR T cell therapy tackle solid tumors with precision?   CAR T cell therapy has proven to be lifesaving for many cancer patients. However, its therapeutic efficacy has encountered limited success in solid tumors.   The challenges:   ❌ CAR T cells cannot access their target efficiently due to the suppressive tumor microenvironment (TME)   ❌ Sparse number of tumor-specific antigens, large tumor heterogeneity   How to address these issues:   ✅ Use TALEN® gene editing technology to create “off-the-shelf” CAR T cells that can be engineered to improve persistence, infiltration and overcome the TME common in solid tumors.   ✅ Inducible "IF/THEN-gated" CAR T-cells   Leverage cancer-associated fibroblasts in the tumor microenvironment (TME) as activators. These cells only become fully functional when they encounter specific TME signals, significantly reducing off-target effects and enhancing safety.   ✅ Breaking through the tumor barrier   By replacing a suppressive T cell protein gene with a second CAR targeting tumor-associated proteins, we can create T-cells that can effectively penetrate and combat the hostile tumor microenvironment – a major hurdle in solid tumor treatment.   This approach allows for customization of the CAR T-cells to respond to different antigens and represents a significant leap towards making CAR T-cell therapy a viable and powerful option for solid tumors. To know more, read the article: https://lnkd.in/exyTMHfs Thoughts? ↪️

This World Cancer Day, let's challenge preconceptions about allogeneic CAR-T cell therapy for blood cancers: 🏹 Myth: Less effective than autologous CAR-T cells. ✅ Reality: Allogeneic CAR-T cells are engineered with high precision to target cancer cells effectively, offering comparable specificity and potency. 🏹 Myth: Take too long to develop. ✅ Reality: Allogeneic CAR-T cells are pre-manufactured and immediately available, reducing critical treatment delays. 🏹 Myth: High risk of graft-versus-host disease (GvHD). ✅ Reality: Innovative gene editing technologies, such as TCR knockout, have significantly reduced the risk of GvHD, making allogeneic CAR-T cells safer to patients. 🏹 Myth: Relapse rates are higher. ✅ Reality: Ongoing innovations in cell durability and persistence are improving long-term outcomes, showing promise in reducing relapse rate. We're committed to developing innovative allogeneic CAR-T cell therapies, uniting cutting-edge science with unique patient needs. Together, we can reimagine cancer care. #WorldCancerDay2025 #UnitedByUnique

❌ The perfect murder: how immune cells eliminate threats? ❌   Imagine your body as a city with immune cells as security forces: 🕵 Macrophages = Detectives who patrol the streets and identify suspicious individuals (antigens) 👮 T-cells = special force unit, who recognize the threat and spring into action. ❗The Call to Action: The macrophage presents the "wanted” antigen to T-cells. The T-cells carefully examine it and decide whether it's a genuine threat. 💡 T-Cell Activation: Once a T-cell confirms the danger, it transforms into an active defender, ready to neutralize the threat. However, sometimes this means turning on the very detective (macrophage) that presented the information—especially if the macrophage has been compromised by the intruder. ❌ Macrophage Sacrifice: To prevent the spread of hidden enemies or overreaction, T-cells may induce apoptosis (programmed cell death) in the macrophage, a necessary sacrifice to protect the city from further harm. ♻️ Recycling and Renewal: Afterward, cleanup crews (healthy macrophages) step in to recycle the remains of the sacrificed cells. This ensures no harmful debris is left behind, keeping the city's streets clean and ready for future challenges. This dance of detection, activation, sacrifice, and renewal is what keeps our immune system functioning like a well-oiled machine, ensuring our body's "city" remains safe and healthy. Thanks again to Nanolive SA for the great video!

On this Martin Luther King Jr. Day, we are reflecting on how we can create positive change in our own spheres of influence - whether through small daily actions or bold, transformative steps.   We believe in the transformative power of ideas and the importance of perseverance in the face of challenges. Martin Luther King Jr.’s dream wasn't just about equality, but about building a society of understanding and opportunity for all.   As we honor Dr. King's legacy, let's continue to push the boundaries of what's possible in biotechnology. We aim to create a healthier world for all.

We are excited to announce that we will attend the J.P. Morgan Healthcare Conference next week in San Francisco (CA)!   Andre Choulika Ph.D. (CEO), Arthur Stril (CBO & CFO) and Dr. Adrian Kilcoyne MD MPH MBA (CMO) are looking forward to connecting with industry leaders, partners, and colleagues to share insights into our progress and outlook. #JPM25